Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

KalVista Pharmaceuticals, Inc. - Common Stock (NQ:KALV)

26.66 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 30, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	748
Open	26.66
Bid (Size)	26.66 (17,000)
Ask (Size)	26.67 (3,400)
Prev. Close	26.66
Today's Range	26.66 - 26.66
52wk Range	9.830 - 26.76
Shares Outstanding	34,233,643
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Unusual volume stocks are being observed in Thursday's session. ↗

April 30, 2026

Via Chartmill

Stock Market Today, April 29: KalVista Pharmaceuticals Surges on Chiesi Group Acquisition Announcement ↗

April 29, 2026

On April 29, 2026, a rare-disease deal reshapes biotech M&A expectations as investors weigh tender terms.

Via The Motley Fool

Performance

YTD	+72.4%	+72.4%
1 Month	+32.4%	+32.4%
3 Month	+70.4%	+70.4%
6 Month	+143.0%	+143.0%
1 Year	+93.6%	+93.6%

More News

Wednesday's session: top gainers and losers ↗

April 29, 2026

Via Chartmill

Which stocks are moving on Wednesday? ↗

April 29, 2026

Via Chartmill

Traders are paying attention to the gapping stocks in Wednesday's session. ↗

April 29, 2026

Via Chartmill

KALV Stock Alert: Halper Sadeh LLC is Investigating Whether KalVista Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders

April 29, 2026

From Halper Sadeh LLC

Via Business Wire

Get insights into the top gainers and losers of Wednesday's pre-market session. ↗

April 29, 2026

Via Chartmill

KalVista Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference

April 08, 2026

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 02, 2026

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Announces Positive Interim Phase 3 Data From KONFIDENT-KID Trial of EKTERLY® (sebetralstat) for Children Aged 2-11 Years at the 2026 Global Angioedema Leadership Conference

March 30, 2026

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Reports Eight Months Fiscal Year 2025 Financial Results and Provides Corporate Update

March 25, 2026

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 2026 Global Angioedema Leadership Conference

March 20, 2026

From KalVista Pharmaceuticals, Inc.

Via Business Wire

Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools ↗

March 18, 2026

Via The Motley Fool

What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down ↗

March 18, 2026

Via The Motley Fool

KalVista Pharmaceuticals to Report Eight Months Fiscal Year 2025 Financial Results and Provide Corporate Update on March 25, 2026

March 18, 2026

From KalVista Pharmaceuticals, Inc.

Via Business Wire

VR Adviser Adds Over 1 Million Savara Shares ↗

March 15, 2026

Via The Motley Fool

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 04, 2026

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Presents New Data Highlighting High Patient Satisfaction and Evolving Treatment Trends with EKTERLY® (sebetralstat)

March 02, 2026

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals to Present at Upcoming Investor Conferences

February 25, 2026

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Announces Inclusion of EKTERLY® (sebetralstat) as a First-Line Therapy for Adolescents 12 and Older in International Pediatric HAE Guideline

February 18, 2026

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals to Present EKTERLY® (sebetralstat) Data at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting

February 12, 2026

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 03, 2026

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Stock Rallies After Hours On Strong Genetic Disorder Drug Sales Kickstart ↗

January 08, 2026

Via Stocktwits

Get insights into the top gainers and losers of Thursday's after-hours session. ↗

January 08, 2026

Via Chartmill

KalVista Pharmaceuticals Provides Update on Strong EKTERLY® Launch with Preliminary Fourth Quarter and Full Year 2025 Revenue Results

January 08, 2026

From KalVista Pharmaceuticals, Inc.

Via Business Wire

Frequently Asked Questions

Is KalVista Pharmaceuticals, Inc. - Common Stock publicly traded?

Yes, KalVista Pharmaceuticals, Inc. - Common Stock is publicly traded.

What exchange does KalVista Pharmaceuticals, Inc. - Common Stock trade on?

KalVista Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for KalVista Pharmaceuticals, Inc. - Common Stock?

The ticker symbol for KalVista Pharmaceuticals, Inc. - Common Stock is KALV on the Nasdaq Stock Market

What is the current price of KalVista Pharmaceuticals, Inc. - Common Stock?

The current price of KalVista Pharmaceuticals, Inc. - Common Stock is 26.66

When was KalVista Pharmaceuticals, Inc. - Common Stock last traded?

The last trade of KalVista Pharmaceuticals, Inc. - Common Stock was at 04/30/26 04:00 PM ET

What is the market capitalization of KalVista Pharmaceuticals, Inc. - Common Stock?

The market capitalization of KalVista Pharmaceuticals, Inc. - Common Stock is 912.67M

How many shares of KalVista Pharmaceuticals, Inc. - Common Stock are outstanding?

KalVista Pharmaceuticals, Inc. - Common Stock has 913M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.